[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495608":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":44,"responsibleParty":66,"collaborators":68,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":25,"enrollmentInfo":85,"targetDuration":25,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":47,"whyStopped":25,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intensive Cancer Screening","EXPERIMENTAL","Usual care plus FDG PET\u002FCT",[13],"Diagnostic Test: FDG PET\u002FCT",{"label":15,"type":6,"description":16,"interventionNames":17},"Usual Care","Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)",[18],"Diagnostic Test: Usual Care",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","FDG PET\u002FCT","F-fluorodeoxyglucose positron emission\u002Fcomputed tomography",[9],null,{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care",[15],[30],{"name":31,"affiliation":5,"role":32},"Dariush Dowlatshahi, MD PhD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","613-798-5555","14709","ddowlat@toh.ca",{"name":40,"role":35,"phone":41,"phoneExt":42,"email":43},"Deborah Siegal, MD","613-737-8899","78060","dsiegal@toh.ca",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The Ottawa Hospital","RECRUITING","Ottawa","Ontario","K1Y 4E9","Canada","CA",{"type":54,"coordinates":55},"Point",[56,57],-75.69812,45.41117,{"lat":57,"lon":56},[60,64,65],{"name":61,"role":35,"phone":62,"phoneExt":25,"email":63},"Michele Demetroff","6137985555","mdemetrof@ohri.ca",{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"name":40,"role":32,"phone":25,"phoneExt":25,"email":25},{"type":67,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[69,71,73],{"name":70,"class":6},"Brain Canada",{"name":72,"class":6},"Heart and Stroke Foundation of Canada",{"name":74,"class":6},"Canadian Stroke Consortium (CSC)","100495608","intensive-cancer-screening-after-cryptogenic-stroke-100495608",false,"NCT05733416","Intensive Cancer Screening After Cryptogenic Stroke","Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial","INCOGNITO","Inclusion Criteria:\n\n* adults ≥18 years\n* presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)\n* patient or delegate willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* contraindications to FDG PET\u002FCT (pregnancy or unable to lie still in bed for 20 minutes)\n* active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)","ALL","18 Years",{"count":86,"type":87},45,"ESTIMATED","INTERVENTIONAL",[90],"NA","The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET\u002FCT (F-fluorodeoxyglucose positron emission\u002Fcomputed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.",[93],"Occult Cancer",[95],"cryptogenic stroke","2025-07-29",{"date":98,"type":99},"2025-07-31","ACTUAL",{"date":101,"type":99},"2023-09-01",{"date":103,"type":87},"2027-01",{"name":5,"class":6},1]